STOCK TITAN
  1. Home
  2. News
  3. BOLT

Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Bolt Biotherapeutics (Nasdaq: BOLT) will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Nov. 14, 2023. The presentation will be available via live webcast on the company's website.
Positive
  • None.
Negative
  • None.

REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, Nov. 14, 2023, at 8:35 a.m. EDT (5:35 a.m. PDT) in New York, New York.

A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s website at www.boltbio.com. Archived replays will be available for 30 days following the event.

About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company leveraging the immune system for a better way to treat cancer. The company is developing novel immunotherapies using an approach that teaches the immune system to recognize and kill cancer in a way that is immediately personalized to each patient. Its pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development and include BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) being evaluated in a Phase 2 trial, and BDC-3042, a myeloid-modulating agonist antibody targeting Dectin-2, being evaluated in a Phase 1 trial. Bolt Biotherapeutics is also developing multiple Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/.

Investor Relations and Media Contact:

Maeve Conneighton
Argot Partners
(212) 600-1902
boltbio@argotpartners.com


The fireside chat will take place on Nov. 14, 2023.

The presentation will be available via live webcast on Bolt Biotherapeutics' website at www.boltbio.com.

Archived replays will be available for 30 days following the event.
Stock BOLT logo
Bolt Biotherapeutics Inc

NASDAQ:BOLT

BOLT Rankings

#4826 Ranked by Market Cap
#3943 Ranked by Stock Gains
N/A Ranked by Dividends

BOLT Latest News

Mar 21, 2024
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Feb 27, 2024
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Dec 5, 2023
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
Nov 9, 2023
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Oct 23, 2023
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

BOLT Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Redwood City

About BOLT

bolt biotherapeutics is a start-up with compelling technology from dr. engleman’s lab at stanford university, which demonstrated complete cures in numerous cancer models. the company is backed by strong life sciences investors and is early in its growth curve, seeking bright, highly motivated individuals that will be the company’s future leaders to help it further develop and bring to patients novel and curative biotherapies.